To investigate the status of immune cell infiltration in melanoma patients treated with immunotherapies, TIMER2.0, a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types, was used to analyse the gene expression data of MAP2K1/2-mutated melanoma. This evidence concerns the gene MAP2K1 and melanoma.